D.R. Wieder, L. Pattimakiel. Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing). „Int J Womens Health”. 2, s. 401–409, 2010. DOI: 10.2147/IJWH.S6162. PMID: 21151688.
K. Oddsson, B. Leifels-Fischer, N.R. de Melo, D. Wiel-Masson i inni. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. „Contraception”. 71 (3), s. 176–182, 2005. DOI: 10.1016/j.contraception.2004.09.001. PMID: 15722066.
H.J. Ahrendt, I. Nisand, C. Bastianelli, M.A. Gómez i inni. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. „Contraception”. 74 (6), s. 451–457, 2006. DOI: 10.1016/j.contraception.2006.07.004. PMID: 17157101.
F.J. Roumen. Review of the combined contraceptive vaginal ring, NuvaRing. „Ther Clin Risk Manag”. 4 (2), s. 441–451, 2008. PMID: 18728840.
D.R. Wieder, L. Pattimakiel. Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing). „Int J Womens Health”. 2, s. 401–409, 2010. DOI: 10.2147/IJWH.S6162. PMID: 21151688.
T.M. Mulders, T.O. Dieben. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. „Fertil Steril”. 75 (5), s. 865–870, 2001. PMID: 11334895.
T.O. Dieben, F.J. Roumen, D. Apter. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. „Obstet Gynecol”. 100 (3), s. 585–593, 2002. PMID: 12220783.
K. Oddsson, B. Leifels-Fischer, N.R. de Melo, D. Wiel-Masson i inni. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. „Contraception”. 71 (3), s. 176–182, 2005. DOI: 10.1016/j.contraception.2004.09.001. PMID: 15722066.
H.J. Ahrendt, I. Nisand, C. Bastianelli, M.A. Gómez i inni. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. „Contraception”. 74 (6), s. 451–457, 2006. DOI: 10.1016/j.contraception.2006.07.004. PMID: 17157101.